Moteur de recherche d’entreprises européennes
Financement de l’UE (8 478 000 €) : Détection précoce et dépistage des hémopathies malignes Hor01/01/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Détection précoce et dépistage des hémopathies malignes
Project SANGUINE addresses the objectives raised by the Cancer Mission Call, which emerged from the growing societal challenge faced by European citizens. According to the European Cancer Information System (ECIS), each year, 2.7 million people in the EU are diagnosed with cancer. The SANGUINE project focuses on hematological malignancies, which account for 10% of those cases, and aims to target the four objectives of the Cancer Mission: (1) understanding, (2) prevention, including screening and early detection, (3) diagnosis, and (4) quality of life improvement of the patients and their relatives. The project introduces a novel minimally-invasive blood test that detects and classifies a set of hematological malignancies. The test is based on detecting a combination of epigenetic biomarkers in DNA from peripheral blood cells and in cell-free DNA. The SANGUINE test will provide superior sensitivity at low-cost which is ideal for screening purposes. This is enabled by direct fluorescent labeling of epigenetic marks in patient DNA and its analysis on a custom designed microarray – the HemaChip. SANGUINE team consists of a comprehensive and strong team of expert that will address medical, technological and social aspects of the developed diagnostic test. Expertise from the medical field includes clinical research, technology development and access to patients. This will enable optimization of the test for hematological malignancies following a user-centric approach and experiencing its implementation in “real-life” clinical settings. The social part of the team includes researchers and patient organization that will promote accessibility of the test to patients and individuals at-risk for screening, early detection and disease management, in combination with a study aiming to increase the screening rates. Ultimately, our project will provide validated reagents, HemaChips and data analysis software ready for large scale screening and early stage commercialization.
| Ethniko Kai Kapodistriako Panepistimio Athinon | 580 500 € |
| European Cancer Organisation | 425 250 € |
| Fakultni Nemocnice Olomouc | 203 625 € |
| FZMB GmbH FORSCHUNGSZENTRUM FUR MEDIZINTECHNIK UND BIOTECHNOLOGIE | 700 200 € |
| JAXBIO TECHNOLOGIES Ltd. | 1 771 875 € |
| Predictby Research And Consulting SL | 290 250 € |
| TEL AVIV UNIVERSITY | 1 283 500 € |
| THE Foundation FOR MEDICAL RESEARCH INFRASTRUCTURAL DEVELOPMENT AND HEALTH SERVICES NEXT TO THE MEDICAL CENTER TEL AVIV | 1 009 250 € |
| UAB ORIENTOS | 534 925 € |
| Univerzita Palackeho V Olomouci | 1 191 500 € |
| VILNIAUS UNIVERSITETO LIGONINE SANTAROS KLINIKOS | 487 125 € |
https://cordis.europa.eu/project/id/101097026
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.